Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869385 | 0.76 | POLB (0.44) | TTBK1TTBK2HTTL3MBTL1MEN1 | |
| SCHEMBL10504189 | 0.69 | HDAC3 (0.41) | L3MBTL1MEN1KMT2ALMNAHDAC3 | |
| SCHEMBL14869383 | 0.68 | GPR84 (0.46) | TTBK1TTBK2HTTL3MBTL1MEN1 | |
| SCHEMBL14869393 | 0.68 | POLB (0.44) | TTBK1TTBK2HTTL3MBTL1MEN1 | |
| SCHEMBL26268886 | 0.67 | CNR1 (0.63) | TSHRTAAR1GPR84MAPK1ALDH1A1 | |
| SCHEMBL10503035 | 0.67 | HDAC3 (0.40) | L3MBTL1MEN1KMT2ALMNAHDAC3 | |
| SCHEMBL18448724 | 0.66 | KDM4E (0.71) | TTBK1TTBK2HTTMEN1KMT2A | |
| SCHEMBL14870277 | 0.64 | TAAR1 (0.40) | TTBK1TTBK2HTTL3MBTL1MEN1 | |
| SCHEMBL14869765 | 0.63 | CA1 (0.57) | — | |
| SCHEMBL8520558 | 0.63 | GPR84 (0.46) | TTBK1TTBK2HTTL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | TTBK1 4010/4885TTBK2 3435/4885HTT 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.